Stability of patients' preferences for chemotherapy: The impact of experience

Medical Decision Making

Volumn 21, Issue 4, 2001, Pages 295-306

  Jansen, Sylvia J T ^a   Kievit, Job ^a   Nooij, Marianne A ^a   Stiggelbout, Anne M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Stability; Standard gamble; Time trade off; Utility assessment

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT CARE;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; HUMANS; MIDDLE AGED; NETHERLANDS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RESEARCH DESIGN; SELF EFFICACY;

EID: 0034934523     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/02729890122062596     Document Type: Article

References (46)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials
2. Adjuvant cytotoxic chemotherapy for early breast cancer: Doubts and decisions
3. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer: A decision-analysis model
4. Patient participation in clinical decision-making for treatment of T3 laryngeal cancer: A comparison of state and process utilities
5. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients
6. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis
7. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer
8. Quality-of-life-adjusted survival for comparing cancer treatments: A commentary on TWiST and Q-TWiST
9. Evaluation of effectiveness: Q-TWiST
10. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival
11. Quality of life assessment for cost/utility studies in cancer
12. Whose utilities for decision analysis?
13. Assessing quality of life and preferences in the seriously ill using utility theory
14. Auranofin therapy and quality of life in patients with rheumatoid arthritis: Results of a multicenter trial
15. A time tradeoff method for measuring quality of life in stage 2 breast cancer patients
16. Cancer patients' evaluations of their current health states: The influences of expectations, comparisons, actual health status, and mood
17. Stability of patient preferences regarding life-sustaining treatments
18. The assessment of values in laryngeal cancer: Reliability of measurement methods
19. Do patients' evaluations of a future health state change when they actually enter that state?
20. Eliciting preferences for alternative drug therapies in oncology: Influence of treatment outcome description, elicitation technique and treatment experience on preferences
21. Unstable preferences: A shift in valuation or an effect of the elicitation procedure?
22. Patient preferences for early discharge after laparoscopic cholecystectomy
23. The utility of different health states as perceived by the general public
24. The time trade-off technique: How do the valuations of breast cancer patients compare to those of other groups?
25. Sensitivity and perspective in the valuation of health status: Whose values count?
26. The effect of individually assessed preference weights on the relationship between holistic utilities and nonpreference-based assessment
27. Measurement of health state utilities for economic appraisal: A review
28. Patients' utilities for cancer treatments: A study of the chained procedure for the standard gamble and time tradeoff
29. Stability of time tradeoff utilities in survivors of myocardial infarction
30. Relationship between health utility and psychometric health status measures
31. When more pain is preferred to less: Adding a better end
32. Understanding patients' decisions: Cognitive and emotional perspectives
33. Patients' memories of painful medical treatments: Real-time and retrospective evaluations of two minimally invasive procedures
34. Prostate cancer patients' utilities for health states: How it looks depends on where you stand
35. Are preferences over health states complete?
36. Whose values in CEA? The impact of "anticipated adaptation"
37. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer
38. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer
39. Application of multi-attribute utility theory to measure social preferences for health states
40. Utility, decision, and quality of life
41. Measuring preferences for health states worse than death
42. Methodological issues of patient utility measurement: Experience from two clinical trials
43. Validation of preferences for life-sustaining treatment: Implications for advance care planning
44. Feasibility, validity and test-retest reliability of scaling methods for health states: The visual analogue scale and the time trade-off
45. Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents